Endometrial Stromal Sarcoma Presenting as Prevesical Mass Mimicking Urachal Tumor

Endometrial stromal sarcoma (ESS) is a mesenchymal neoplasm that usually occurs as a primary tumor of the uterine corpus, but rarely arises in other sites, such as the ovary, pelvic cavity, mesentery, omentum and intestine. Herein, we present a rare case of low-grade ESS presented as prevesical mass. A 60-yr-old woman who had undergone total hysterectomy for endometriosis eleven years ago was presented with incidentally detected prevesical pelvic mass. Since malignant transformation of urachal remnants was possible, the mass was suspected to be a urachal tumor. Extraction of the mass was performed, and the histopathologic diagnosis was low-grade ESS. In summary, prevesical tumor is rare but in patients with endometriosis, we suggest endometriosis and its possible malignant changes should be taken into account in the differential diagnosis of prevesical mass.

Key Words : Sarcoma, Endometrial Stromal; Endometriosis

INTRODUCTION

Endometrial stromal sarcoma (ESS) is a rare neoplasm comprising only 0.2% of all uterine malignancies and usually occurs as a primary tumor of the uterine corpus (1). ESS of extraterrine origin is a very rare type of neoplasm and arises in sites, such as the ovary, pelvic cavity, mesentery, omentum, and serosal or intramural portion of the large intestine (2-4). The tumor is usually classified into two subtypes, low-grade ESSs and undifferentiated sarcomas with the latter subtype carrying a very poor prognosis (5, 6).

We describe a 60-yr-old woman with low-grade ESS presented as prevesical mass mimicking urachal mass.

CASE REPORT

A 60-yr-old woman presented with incidentally detected prevesical mass. Her history was remarkable in that she had a total hysterectomy by lower median abdominal incision for endometriosis 11 yr ago. The family history was unremarkable. Physical examination showed no palpable abdominal mass. Routine blood tests, blood chemistry and urine test revealed no abnormal findings. In the previous ultrasonographic examination, heterogeneous hyperechoic pelvic mass was incidentally detected, and she was transferred to our hospital.
DISCUSSION

ESS usually occurs as a primary tumor of the uterine corpus and is rare neoplasm. ESS of extrauterine origin is very rare. Because of the rarity of ESS, very little is known about its pathogenesis. However, there have been some reports in which ESS is considered to be associated with endometriosis (2-4). It arises in area of pre-existing endometriosis and also arises in cases that are not associated with endometriosis.

These are explained by two hypotheses. One is malignant transformation of endometriosis. Various types of neoplasm have been observed in patients with endometriosis.

Histologically, endometrial adenocarcinoma is the most (about 70%), and sarcoma is the second common malignancy (12%) (7). But exact incidence of ESS in endometriosis is not well described. Heaps et al. (7) reported that malignant tumor arising in endometriosis involved ovary (78.7%) and extragonadal site (21.3%).

Majority of extragonadal sites were rectovaginal septum (4.3%), colon (4.3%), vagina (2%), and pelvic peritoneum (5.7%). The other theory is a de novo tumor, potentially derived from submesothelial pluripotential Mullerian cells. The pluripotential Mullerian epithelium is considered to be widely distributed in the abdominal and pelvic cavities (4).

In the present case, the patient had undergone total hysterectomy for endometriosis 11 yr ago, and the tumor was localized in the prevesical space. So, we assumed that it arose from prevesical endometriosis because the patient had a history of endometriosis but there is no direct evidence.

Previously, the tumor is usually classified into two categories, low and high-grade, based on differences in mitotic activity, with the latter subtype carrying a very poor prognosis (5). Recently, the World Health Organization classification for tumors of the uterus classifies the tumors based primarily on tumor margin status and cytologic features (6). Low-grade ESSs are clinically indolent malignancies with minimal cyto-
logic atypia and proliferative activity. Undifferentiated sarcomas (previously categorized as high-grade endometrial stromal sarcomas) are highly aggressive malignancies that show substantial cytologic atypia and high mitotic activity.

Young et al. (3) reported that the mitotic rate of the extraterine ESS correlated with the prognosis but Chang et al. (2) reported that neither mitotic index nor cytologic atypia in primary extraterine ESS were predictive of tumor recurrence or death from tumor. In their series, 77% of patients whose tumors had a mitotic index of less than 10 per HPF had one or more recurrences and 30% died from their neoplasm. The behavior of the primary extraterine ESS was more reminiscent of high-grade primary uterine ESS than low-grade primary uterine ESS (2). Therefore, close observation and extended follow-up will be required in extraterine ESS, regardless of mitotic activity.

Low-grade ESS has slow growth and indolent course with a tendency for late recurrence; approximately 50% of cases of low-grade ESS develop recurrent disease (6). A relatively long-term survival, despite tumor dissemination, has been reported in low-grade ESS cases. Both recurrent and metastatic low-grade sarcomas can be successfully treated with surgical excision, radiation, progestin therapy, or a combination therapy (6). Considering highly recurrent nature of extraterine ESS or low-grade ESS, a life long follow-up is necessary for this patient.

Tumor localized in the prevesical space is very rare but urinary tumor has been most commonly presented in prevesical space. However, when patient with endometriosis presented with prevesical mass in Retzius space, endometriosis and its possible malignant changes should be taken into account in differential diagnosis.

REFERENCES

1. Silverberg SG, Kurman RJ. Endometrial stromal tumors. In: Silverberg SG, Kurman RJ, eds. Atlas of tumor pathology. 3rd ed. Washington D.C: Armed forces institute of pathology; 1992: 91-111.
2. Chang KL, Crabtree GS, Lim-Tan SK, Kempson RL, Hendrickson MR. Primary extraterine endometrial stromal neoplasms: a clinicopathologic study of 20 cases and a review of the literature. Int J Gynecol Pathol 1993; 12: 282-96.
3. Young RH, Prat J, Scully RE. Endometrioid stromal sarcomas of the ovary. A clinicopathologic analysis of 23 cases. Cancer 1984; 53: 1143-55.
4. Fukunaga M, Ishihara A, Ushigome S. Extraterine low-grade endometrial stromal sarcoma: report of three cases. Pathol Int 1998; 48: 297-302.
5. Norris HJ, Taylor HB. Mesenchymal tumors of the uterus. I. A clinical and pathological study of 53 endometrial stromal tumors. Cancer 1966; 19: 755-66.
6. Hendrickson MR, Tavassoli FA, Kempson RL, McCluggage WG, Haller U, Kubik-Huch RA. Mesenchymal tumours and related lesions. In: Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Breast and Female Genital Organs. Lyon, France: IARC Press; 2004: 233-6.
7. Heaps JM, Nieberg RK, Berek JS. Malignant neoplasms arising in endometriosis. Obstet Gynecol 1990; 75: 1023-8.